{"entity":{"id":"nct06878625","kind":"trial","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","summary":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT06878625 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 138 participants, started 2024-12-06 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sacituzumab Govitecan combined with Toripalimab; Sacituzumab govitecan combined with anti-angiogenesis. Conditions listed: Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histologically confirmed triple-negative invasive breast cancer, defined as immunohistochemical detection of ER \\< 10%, PR \\< 10%, HER2 0-1+ or HER2 2+ with negative FISH or CISH results, in accordance with the 2018 ASCO-CAP HER2-negative identification guidelines\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06878625","url":"https://clinicaltrials.gov/study/NCT06878625"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06878625","phase":"2","setting":"A Multicenter, Prospective, Cohort Study Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":138,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06878625/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}